PT  - JOURNAL ARTICLE
AU  - Haile, Eiftu S.
AU  - Sotimehin, Ayodeji E.
AU  - Gill, Bradley C.
TI  - Medical management of benign prostatic hyperplasia
AID  - 10.3949/ccjm.91a.23027
DP  - 2024 Mar 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 163--170
VI  - 91
IP  - 3
4099  - http://www.ccjm.org/content/91/3/163.short
4100  - http://www.ccjm.org/content/91/3/163.full
SO  - Cleve Clin J Med2024 Mar 01; 91
AB  - Medical management of benign prostatic hyperplasia (BPH) has progressed gradually in recent years and remains the starting point for most symptomatic patients seeking treatment. Beyond well-known alpha-blockers and 5-alpha reductase inhibitors, there is growing evidence for the use of phosphodiesterase-5 inhibitors and beta-3 agonists in managing the condition, which may afford additional relief of “bothersome” symptoms in some patients. This review details contemporary medical management of BPH with an emphasis on the indications for certain classes of pharmacotherapy and their relative benefits and side effects. Surgical and procedural treatment of BPH is covered in a separate review.